E.ZabolianA.SalekiH.YavariM.et al (2020)
In trials, it has produced weight loss exceeding 24% of baseline weight
Tirzepatides Indian patent runs until at least 2030, so Cipla isnt fighting any generic competition at all
GLP-1R agonists improve the metabolic status of diabetic patients through a variety of mechanisms, which provides a new strategy and direction for the treatment of T2DM
Efectos secundarios GI frecuentes Nuseas Semaglutida 2,4 mg ~44 % Tirzepatida 15 mg ~31 % Retatrutida 12 mg ~45 % Diarrea Semaglutida 2,4 mg ~30 % Tirzepatida 15 mg ~23 % Retatrutida 12 mg ~39 % Vmitos Semaglutida 2,4 mg ~24 % Tirzepatida 15 mg ~12 % Retatrutida 12 mg ~20 % Estreimiento Semaglutida 2,4 mg ~24 % Tirzepatida 15 mg ~11 % Retatrutida 12 mg ~16 % Interrupcin por EA Semaglutida 2,4 mg ~7 % Tirzepatida 15 mg ~6 % Retatrutida 12 mg ~6 % Algunas observaciones de los datos publicados: Semaglutida tiene un perfil GI bien caracterizado a partir de un uso clnico extenso
Think of GSH as a lighthouse in foggy autoimmune seas, guiding ships (immune cells) safely home